
Pacira BioSciences, Inc.: quarterly results
Price
$36.48
November 16, 2026Market cap $1.5B
What Ploutos Investor adds for Pacira BioSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
Results, quarter by quarter
When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.
Next results
last Nov 5, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
Every release
Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.
- Q3 2026Stock, next session–
- Q2 2026Stock, next session–
- Q1 2026Stock, next session–
- Q4 2025Stock, next session–
| Quarter | Released | Revenue | EPS | Stock, next session | S&P 500 | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 5, 2026 | $177M-1.6% | $0.70+483.3% | – | – | 10-Q |
| Q2 2026 | Aug 4, 2026 | $192M+6.2% | $0.12 | – | – | 8-K |
| Q1 2026 | Apr 30, 2026 | $177M+5.0% | $0.07-30.0% | – | – | 8-K |
| Q4 2025 | Feb 26, 2026 | $197M+5.1% | $0.04-89.5% | – | – | 8-K |
Every release
PCRX's results days and the share's move after each, from Q3 2018 to Q4 2025, 64 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 8 quarters.
and 59 more, back to Q3 2018
Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one. Where a 10-Q or 10-K is named, the results came only in that report: the company put out no press release (8-K) for them.
The full analysis
What do Pacira BioSciences's filings show?
The results say what Pacira BioSciences reported. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.